The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
The Covid-19 pandemic revealed how tenuous our global supply chains are. Everyone felt the sting from increased demand of certain items and reduced manufacturing. A pandemic is just one root cause of a material supply disruption. Increased demand of items which close manufacturing processes have led to shortages of single-use technology such as product bags or filters. Biologics, Medical Devices and Pharmaceuticals use thousands of materials to manufacture their products and disruption to the supply of just one of those items can wreak havoc on manufacturing schedules and the ability to ensure consistent supply to the patient. Performing a monosource material risk assessment provides the structure to prioritize and evaluate materials in order to develop a practical mitigation strategy and implement controls that will help ensure a steady supply of manufacturing materials.
Speaker(s):
Lesley
Merkle,
Associate Director Quality Compliance, Site Risk Champion,
Sanofi
You must be logged in and own this session in order to
post comments.